Improvement in Coronary Vascular Dysfunction Produced with Euglycaemic Control in Patients with Type 2 Diabetes

Overview

Journal Heart

Date 2006 Aug 31

PMID 16940388

Citations 19

Authors

T H Schindler

A D Facta

J O Prior

J Cadenas

W A Hsueh

M J Quinones

H R Schelbert

Affiliations

Soon will be listed here.

Abstract

Objective: To determine the effect of plasma glucose lowering on coronary circulatory function in type 2 diabetes mellitus.

Methods: Twenty patients with type 2 diabetes and 18 weight-matched controls were studied. At baseline, myocardial blood flow (MBF) was measured with [(13)N]ammonia and positron emission tomography at rest, during cold pressor testing (CPT), and during adenosine hyperaemia. In diabetic patients, MBF and blood chemistry were analysed again after 3 months of glucose-lowering treatment with glyburide and metformin.

Results: Although hyperaemic MBF did not differ significantly between the patients and controls (1.81 (0.38) v 1.97 (0.43) ml/min/g; mean (SD)), the CPT-induced MBF increase (DeltaMBF) was significantly less in diabetic patients than in controls (0.07 (0.07) v 0.25 (0.12) ml/min/g; p<0.001). Treatment with glyburide and metformin significantly decreased plasma glucose concentrations from 207 (76) to 134 (52) mg/dl (p<0.001). This decrease in plasma glucose was paralleled by a significant increase in DeltaMBF in response to CPT (0.20 (0.16) from 0.07 (0.07) ml/min/g; p<0.001), which tended to be lower than in controls at baseline (0.20 (0.16) v 0.25 (0.12) ml/min/g; p = NS). The decrease in plasma glucose concentrations correlated significantly with the improvement in DeltaMBF in response to CPT (r = 0.67, p<0.01).

Conclusions: Type 2 diabetes mellitus is associated with abnormal MBF response to CPT, which can be significantly improved by euglycaemic control with glyburide and metformin. The close association between the decrease in plasma glucose concentration and the improvement in coronary vasomotor function in response to CPT suggests a direct adverse effect of raised plasma glucose concentration on diabetes-related coronary vascular disease.

Citing Articles

Effect of sampling rate during dynamic myocardial CT perfusion on coronary flow reserve and ischemia analysis.

Tomizawa N, Ozu H, Kamio S, Fujimoto S, Nozaki Y, Fan R Int J Cardiovasc Imaging. 2025; .

PMID: 39992566 DOI: 10.1007/s10554-025-03361-6.

Effect of Luseogliflozin on Myocardial Flow Reserve in Patients with Type 2 Diabetes Mellitus (LUCENT-J Study).

Tamanaha T, Makino H, Son C, Koezuka R, Tochiya M, Omura-Ohata Y Diabetes Ther. 2024; 15(5):1245-1254.

PMID: 38573468 PMC: 11043273. DOI: 10.1007/s13300-024-01571-0.

Patient factors and outcomes associated with discordance between quantitative and qualitative cardiac PET ischemia information.

Zigray H, Elman S, Cheng R, Li S, Lee J, Soine L PLoS One. 2021; 16(3):e0246149.

PMID: 33657111 PMC: 7928488. DOI: 10.1371/journal.pone.0246149.

The cardiovascular determinants of physical function in patients with end-stage kidney disease on haemodialysis.

Adenwalla S, Billany R, March D, Gulsin G, Young H, Highton P Int J Cardiovasc Imaging. 2020; 37(4):1405-1414.

PMID: 33258084 PMC: 8026413. DOI: 10.1007/s10554-020-02112-z.

Thoracic fat volume is independently associated with coronary vasomotion.

Dunet V, Feihl F, Dabiri A, Allenbach G, Waeber B, Heinzer R Eur J Nucl Med Mol Imaging. 2015; 43(2):280-287.

PMID: 26283503 DOI: 10.1007/s00259-015-3160-0.

References

Di Carli M, Bianco-Batlles D, Landa M, Kazmers A, Groehn H, Muzik O . Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus. Circulation. 1999; 100(8):813-9. DOI: 10.1161/01.cir.100.8.813. View

Schindler T, Cardenas J, Prior J, Facta A, Kreissl M, Zhang X . Relationship between increasing body weight, insulin resistance, inflammation, adipocytokine leptin, and coronary circulatory function. J Am Coll Cardiol. 2006; 47(6):1188-95. DOI: 10.1016/j.jacc.2005.10.062. View

Pop-Busui R, Kirkwood I, Schmid H, Marinescu V, Schroeder J, Larkin D . Sympathetic dysfunction in type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction. J Am Coll Cardiol. 2004; 44(12):2368-74. DOI: 10.1016/j.jacc.2004.09.033. View

Kaufmann P, Camici P . Myocardial blood flow measurement by PET: technical aspects and clinical applications. J Nucl Med. 2005; 46(1):75-88. View

Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo R . beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab. 2004; 90(1):493-500. DOI: 10.1210/jc.2004-1133. View

Lerman A, Zeiher A . Endothelial function: cardiac events. Circulation. 2005; 111(3):363-8. DOI: 10.1161/01.CIR.0000153339.27064.14. View

Fitzgerald S, Kemp-Harper B, Tare M, Parkington H . Role of endothelium-derived hyperpolarizing factor in endothelial dysfunction during diabetes. Clin Exp Pharmacol Physiol. 2005; 32(5-6):482-7. DOI: 10.1111/j.1440-1681.2005.04216.x. View

Schindler T, Nitzsche E, Schelbert H, Olschewski M, Sayre J, Mix M . Positron emission tomography-measured abnormal responses of myocardial blood flow to sympathetic stimulation are associated with the risk of developing cardiovascular events. J Am Coll Cardiol. 2005; 45(9):1505-12. DOI: 10.1016/j.jacc.2005.01.040. View

Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M . Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res. 2001; 88(2):E14-22. DOI: 10.1161/01.res.88.2.e14. View

10.

Mather K, Verma S, Anderson T . Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol. 2001; 37(5):1344-50. DOI: 10.1016/s0735-1097(01)01129-9. View

11.

Sundell J, Knuuti J . Insulin and myocardial blood flow. Cardiovasc Res. 2003; 57(2):312-9. DOI: 10.1016/s0008-6363(02)00718-6. View

12.

Economides P, Caselli A, Tiani E, Khaodhiar L, Horton E, Veves A . The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. J Clin Endocrinol Metab. 2004; 89(2):740-7. DOI: 10.1210/jc.2003-031116. View

13.

Vehkavaara S, Yki-Jarvinen H . 3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2003; 24(2):325-30. DOI: 10.1161/01.ATV.0000113817.48983.c5. View

14.

Fisher M . Diabetes and atherogenesis. Heart. 2004; 90(3):336-40. PMC: 1768108. DOI: 10.1136/hrt.2003.018622. View

15.

Schindler T, Nitzsche E, Olschewski M, Brink I, Mix M, Prior J . PET-measured responses of MBF to cold pressor testing correlate with indices of coronary vasomotion on quantitative coronary angiography. J Nucl Med. 2004; 45(3):419-28. DOI: 10.1097/00006231-200404000-00092. View

16.

Feher M . Diabetes: preventing coronary heart disease in a high risk group. Heart. 2004; 90 Suppl 4:iv18-21. PMC: 1876314. DOI: 10.1136/hrt.2004.037572. View

17.

Cradock S . Helping patients to improve self management of diabetes. Heart. 2004; 90 Suppl 4:iv36-8. PMC: 1876317. DOI: 10.1136/hrt.2004.037622. View

18.

Sundell J, Janatuinen T, Ronnemaa T, Raitakari O, Toikka J, Nuutila P . Diabetic background retinopathy is associated with impaired coronary vasoreactivity in people with Type 1 diabetes. Diabetologia. 2004; 47(4):725-31. DOI: 10.1007/s00125-004-1340-8. View

19.

Vanhoutte P, Miller V . Alpha 2-adrenoceptors and endothelium-derived relaxing factor. Am J Med. 1989; 87(3C):1S-5S. DOI: 10.1016/0002-9343(89)90496-8. View

20.

Nitenberg A, Valensi P, Sachs R, Dali M, Aptecar E, Attali J . Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes. 1993; 42(7):1017-25. DOI: 10.2337/diab.42.7.1017. View